Systemic sclerosis & Raynaud's
Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course
Authors' conclusion
These data suggest that five distinct scleroderma immune responses, alone or in combination, may be useful tools to stratify the risk of cancer for scleroderma patients.
Study context
- Population
- Scleroderma patients from the Johns Hopkins Scleroderma Center and the University of Pittsburgh Scleroderma Center
- Participants
- 676 vs 687
- Comparison
- Scleroderma autoantibody profiles in SSc patients with cancer vs SSc controls without cancer
- Casesn = 676
- Controlsn = 687reference
- Outcome
- Association of distinct scleroderma autoantibodies with overall cancer at any time
Methodological detailstwo-centre, logistic regression adjusted for relevant covariates, random forest analysis
- Two-centre
- Logistic regression adjusted for relevant covariates
- Random forest analysis
Main finding
As reported in the abstract
Overall cancer risk by autoantibody (adjusted)
Anti-POLR3, OR (95% CI 1.03-2.11), increased risk
1.47
Monospecific anti-Ro52, OR (95% CI 1.29-3.74), increased risk
2.19
Anticentromere, OR (95% CI 0.51-0.93), lower risk
0.69
Anti-U1RNP, OR (95% CI 0.43-0.93), lower risk
0.63
Observational data: associations, not effects.
Further findings
Cancer-associated scleroderma (cancer within 3 years of scleroderma onset) by autoantibody
- Anti-POLR3, OR
- 2.28 (95% CI 1.33-3.91)
- Monospecific anti-Ro52, OR
- 2.58 (95% CI 1.05-6.30)
- Anticentromere, OR
- 0.39 (95% CI 0.20-0.74)
- Anti-U1RNP, OR
- 0.32 (95% CI 0.11-0.93)
Autoantibody combinations
- Anti-Ro52 plus anti-U1RNP or anti-Th/To associated with decreased cancer risk vs anti-Ro52 alone
Original publication
Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course. Arthritis Rheumatol. Published 27 November 2023. doi:10. 1002/ art. 42663
Composed by AI from the published abstract and checked against it. How Briefs are made →